Safety and Next Steps
GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate, most commonly consisting of local injection site reactions.
The company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS. Sellas is eyeing a potential BLA submission in the first half of 2027.
"Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible," CEO Angelos Stergiou said.
Sellas is now conducting further analyses of the results, which will be presented at an upcoming major medical conference and submitted for publication in a peer-reviewed medical journal.
Sources
This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.